Zimmer Biomet Holdings, Inc.

and welcome to the Zimmer Biomed third quarter 2025 earnings conference call. If anyone needs assistance at any time during the conference, please press the star followed by the zero. As a reminder, this conference is being recorded today, November 5th, 2025. Following today's presentation, there will be a question and answer session. At this time, all participants are in a listen-only mode. If you have a question, please press the star followed by the one on your push-button phone. I would now like to turn the conference over to David DiMartino, Senior Vice President, Investor Relations.

Thank you, Operator, and good morning, everyone. Welcome to Zimmerman Biomet's third quarter 2025 earnings conference call. Joining me on today's call are Yvonne Tornos, our Chairman, President, and CEO, and Sukhia Patia, our CFO in EVP Finance, Operations, and Supply Chain. Before we get started, I'd like to remind you that our comments during this call will include forward-looking statements. Actual results may differ materially from those indicated by the forward-looking statements due to a variety of risks and uncertainties. For a detailed discussion of all these risks and uncertainties, in addition to the inherent limitations of such forward-looking statements, please refer to our ICC filings. Please note, we assume no obligation to update these forward-looking statements, even if actual results or future expectations change materially. Additionally, the discussions on this call will include certain non-GAAP financial measures, some of which are forward-looking non-GAAP financial measures. Reconciliation on these measures to the most directly comparable GAAP financial measures and an explanation of our basis for calculating these measures is included within our third quarter earnings release, which can be found on our website, zimmerblattmat.com. With that, I'll turn the call over to Yvonne. Yvonne?

Thank you, David. Good morning, everyone, and thank you for joining today's call. I want to start today the way that I always start, by sharing my sincere gratitude to the Zimmer Biomed team members around the world who move our business and mission forward each and every day. Thank you for your tireless work, your dedication to solving the most pressing challenges in healthcare, and thank you for your relentless commitment to serving our customers and their patients. Today, Zimmer Biomed is a totally different company than it was just a few years ago, and this is thanks to your efforts. Through my prepared remarks, I'm going to cover three key areas. First, I'm going to summarize the third quarter results and review the momentum of our recently launched new products, which has strongly validated our innovation cycle, while I'm also going to briefly cover some of the commercial execution improvements that we are making and will continue to make. Secondly, I'll address our updated 2025 guidance. And third, I'll cover the three key strategic priorities of Zimmer Biomed, people and culture, operational excellence, and innovation and diversification. Starting with the third quarter, we grew sales 5% on an organic constant currency basis with our critical US business accelerating 330 basis points sequentially to 5.6% from 2.3% in the second quarter. This is the best revenue growth performance in the US since the middle of 2023, with the US being the largest business here at Zimmer Biomed. That said, late in the quarter, unexpected weakness in Eastern Europe, Latin America, and non-core segments of SEP, namely restorative therapies, impacted our growth by nearly 120 basis points for the quarter. Importantly, we have identified the issues, are moving swiftly to address them, and are contemplating these headwinds in these three areas in the guidance that we are providing for the year 2025. Overall, we are very confident in our actions and remain highly enthusiastic about the early market reception of our new products and the upcoming launches, which we do believe will be catalysts for growth. Equally important, we continue to see healthy market growth rates fueled by demographics, start-up care dynamics like the shift to the ASC, Ambulatory Surgical Center environment, here in the U.S., and broader adoption of technology. Unpacking or U.S. performance for the second consecutive quarter, here in 2025, needs accelerated sequentially with growth of 3.5% or up 180 basis points from 1.7% growth in the second quarter of 2025. This was driven by adoption of Persona Osteotide, or total cementless knee, and Oxford, or partial cementless knee, which is performing above our internal expectations when it comes to post-training adoption rates. Specifically, Persona Osteotide now represents nearly 30% of our U.S. total knee implants and will remain on track to exceed 50% final penetration by the end of 2027. Next, our robotics and navigation strategy of offering a comprehensive and differentiated suite of customer-centric technology solutions is resonating deeply with surgeons. U.S. technology and data, bone cement, and surgical cells increased 20.3% this quarter, driven by the strongest robotics capital sales quarter in more than a year. Importantly, utilization continues to increase, with U.S. ROSA accounts now performing over half of their knee implants robotically, up 400 basis points for the year. U.S. HIPS were up 4% in the quarter, as our triple play of Z1, Hemer, and OrthoGrip continues to gain traction. Z1, or triple tapered stem, accounted for over 25% of hip stems in the third quarter of the year, and Hemer, or surgical impactor, the utilization rates doubled through the first nine months of the year to 20%. Finally, our U.S. SCT business continues to benefit from new product launches, growing 6.4% in the quarter, up over 250 basis points sequentially from 3.9% growth in the second quarter of this year, and this is in despite of the weakness in restorative therapies that I mentioned earlier. Our decision to invest more in high-growth areas is showing great returns. For example, our upper extremities business increased in the high single digits, driven by our identity total solder and osteophyte stemless solder. for which 80% of users were competitive accounts. In addition, one of our most exciting businesses, CMFT, Cranial Maxillofacial Thoracic, was up over 20% on the back of new product introductions in rib trauma, cardiac surgery, and neuroablation. CMFT continues to be a recipient of investment, and we foresee a bright future for this platform for many quarters and years to come. For 2025, with updating our full-year organic constant currency revenue growth expectations to a range of 3.5% to 4% from our previous 3.5% to 4.5% range. This excludes the contribution from Paragon 28, while we are maintaining our 2025 adjusted EPS guidance of $8.10 to $8.30. The updated revenue range contemplates, number one, continued weakness in restorative therapies. Number two, a more measured outlook for certain international emerging markets while we address some of the challenges that we saw late in the quarter here in Q3. And thirdly, the modest slowdown in the U.S. revision market for both hips and knees persisting throughout the rest of 2025. Suki is going to provide more detail on guidance during his prepared remarks. We are continuing to transform Zimba Biomed at a rapid pace to achieve our long-term ambitions. Let me start now in closing some of the updates relevant to the three key priorities of our organization. Again, those being people and culture, operational excellence, and innovation and diversification. Starting with people and culture, we are committed to having the right people in the right roles so we can consistently execute owner strategy without hiccups. We owe this to all of our stakeholders, those being patients, customers, employees, and investors. We hold the team to this standard and will continue to make performance-based changes when commitments are not made. Along with that approach and reflected in the guidance that we're providing today for 2025, we are making leadership and governance changes in some of our international businesses to address some of the headwinds that we have seen in these geographies throughout the year 2025. Also in the U.S., our group president, Kevin Thornton, continues to drive the U.S. channel transformation at the right pace, showing promising results as we demonstrated in our Q3 third quarter results. These changes include bringing in new sales leadership for ASCs, ambulatory surgical centers, for SET, and for key account management, while we also continue to drive a sales incentive plan which increasingly rewards growth. Kevin is leading tremendous efforts to drive sales excellence, and he and the team continue to implement sales force specialization for key growth categories, such as robotics and SET. Additionally, we have installed new leadership in restorative therapies, And we have changed reporting lines in some of our U.S. businesses to drive maximum visibility, consistency, and accountability. Again, all of these changes are contemplated in the guidance that we are providing. I'm confident that the best is yet to come here at Zimmer Biomed as we continue to merge best-in-class innovation with solid and consistent commercial execution. Now, turning to our second key priority, operational excellence. This strategic pillar encompasses efforts on both the top and bottom line to accelerate revenue growth, improve margins, and increase free cash flow generation through inventory management. I'm proud of the work that the team has done in 2025 to drive adjusted EPS and free cash flow. The efforts of the team have enabled Zimmer Biomed to grow adjusted earnings per share in 2025 versus 2024 and this is in the backdrop of executing two significant M&A deals, Monogram and Paragon 28, absorbing the impact from tariffs and making meaningful commercial investments that will yield meaningful growth in quarters and years to come. Meanwhile, the focus on reducing days of inventory on hand underpins our strategy to increase free cash flow, and we continue to see progress in this area. Finally, In the third priority of innovation and diversification, very excited to share that on October the 7th, we closed the acquisition of Motogram Technologies, which is the company behind the embossed, semi, and fully autonomous AI-driven orthopedic robotic system. A few weeks ago, we held initial demonstrations of this technology at the HEEP and eSociety meeting in Dallas, Texas, to a selected group of around 100 surgeons, most of them currently using competitive technology. We walked away extremely energized by their feedback. This technology is already changing the conversation, and with data and time, we expected to also change the standard of care. In a healthcare system which continues to be constrained by cost, and in an orthopedic environment where physicians and staff are desperately seeking more efficient ways to deliver best-in-class patient care, we believe that EMBOSS, will offer an elegant and compelling solution. That said, we're not betting on just one platform. We believe in optionality, customer-centricity, and flexibility. The Monogram technology is one part of our very comprehensive suite of customer-centric offerings, which range from simplified navigation such as OrthoGrid to non-CT, non-CAT scan-based robotics with ROSA to meet the diverse needs of our broad range of global customers. We now look forward to completing the clinical protocols for Monogram, which started back in early July, and to launch the world's first semi-autonomous robot with persona implants, the world's leading knee implant, in early 2027, swiftly followed by the fully autonomous platform at the end of 2027 or early 2028. Relative to our diversification mandate, we continue to see the integration of Paragon 28 moving at the right pace and in the right direction. And our expectations for this business remain unchanged for the year 2025 and beyond. There continues to be a strong excitement for the opportunity as we launch new products and continue to integrate commercially. In addition to Monogram, we continue to deliver on a broader innovation roadmap, bringing new to the world technologies. These include iodine-treated HIP in Japan, for which we recently received PMDA approval. This is a first-of-the-world technology that inhibits bacterial adhesion and biofilm formation on the implant surface to address PJIs, periprosteric joint infections. We launched in before the end of 2025 ROSA with Optimize, which has a simplified user interface and offers kinematic alignment for knee implants. We're also deeply in launch mode for next generation foot and ankle products. These come in mostly from Paragon 28 and include fusion plating and other key growth areas within lower extremities. Groundbreaking technologies coming from Zimmer Biomed as part of our digital ecosystem to complement our leading positions and drive core implants. And then lastly, we have over 20 new products in ACT over the strategic horizon which address safety, efficiency, and best-in-class clinical and economic outcomes. In conclusion, we are very proud of the progress in our organization and are excited about the future ahead. We're going to continue to bet boldly on innovation that changes the standard of care in high-growth areas while we continue to improve commercial execution. Along the way, as we responsibly reposition the organization for higher growth, we're going to remain highly disciplined on capital allocation ensuring that this company remains synonymous with a strong earnings growth and free cash flow generation. And with that, I'll now turn the call over to Suki. Thank you.

Thanks and good morning, everyone. This quarter, we grew sales 5% on an organic constant currency basis and delivered adjusted earnings per share of $1.90, which was up 9.2% year over year, despite dilution from the Paragon 28 transaction the impact of tariffs, and continued investments in our commercial organization. As Vaughn mentioned, we are encouraged by the progress of the U.S. business, which was up 5.6% on an organic constant currency basis year over year, driven by our new product cycle. This performance was partially offset by headwinds in emerging markets and certain non-core businesses that negatively impacted growth in the quarter by over 100 basis points. As we get into the details of the results, unless otherwise noted, my statements will be about the third quarter of 2025 and how it compares to the same period in 2024. And my commentary will be on a constant currency and adjusted operating basis. 2025 organic constant currency commentary and guidance excludes the impact from the Paragon 28 acquisition that closed in April. Net sales were $2 billion, an increase of 9.7% on a reported basis and 5%. excluding the impact of foreign currency and the Paragon 28 acquisition. Consolidated pricing was 20 basis points positive in the quarter. Our U.S. business grew 5.6% on an organic basis, which reflects increasing customer adoption of recently launched products and strong robotic placements. Internationally, we grew revenue 4.2%, where emerging markets represented a headwind to growth. Global knees grew 5.3% in the quarter, with the U.S. increasing 3.5% and internationally increasing 7.8%. This U.S. performance was driven by increasing penetration of our Persona Osseotide cementless total knee and continued adoption of our Oxford partial cementless knee. International growth benefited from new products and the timing of orders in EMEA, which were partially offset by lower growth in China. HITS grew 3.8%, with the U.S. increasing 4% and international increasing 3.6%. The U.S. growth was a result of our triple play of Z1, Hammer, and OrthoGrid, driving share of wallet and competitive conversions. Next, our SET segment grew 3.6% globally on an organic basis, with low teens growth in CMFT and high single-digit growth in upper extremities, partially offset by a low teens decline in restorative therapies. Finally, technology and data, bone cement, and surgical increased 11.3 percent globally, with strong ROZA placements during the quarter. Now turning to our P&L. We reported GAAP diluted earnings per share of $1.16 compared to GAAP diluted earnings per share of $1.23 in the prior year. Higher revenue, a decrease in acquisition and integration related charges, and lower share count were offset by higher interest expenses due to the Paragon 28 transaction, and a step-up in year-over-year tax tied to certain one-time favorable items in the prior year. On an adjusted basis, we delivered diluted earnings per share of $1.90 compared to $1.74 in the prior year. This increase was driven by higher revenue, improved gross margin, and a lower share count, partially offset by a step-up in interest expense tied to the Paragon 28 transaction. Adjusted gross margin was 72.6%, higher than the third quarter of 2024 due to lower manufacturing costs and favorable mix. Adjusted operating margin was 26.5%, modestly higher than the prior year as a result of better gross margin, partially offset by increased commercial investments and the addition of Paragon 28. Adjusted net interest and non-operating expenses were 72 million, above the prior year, driven by higher debt related to Paragon 28, and higher interest rates on refinance debt that matured in 2024. Our adjusted tax rate was 17.8%, and fully diluted shares outstanding were 198.8 million, down year over year due to share repurchases in 2024 and in the first quarter of 2025. Now turning to cash and liquidity, we had another strong quarter of cash generation, with operating cash flows of 419 million and free cash flow of 278 million, bringing year-to-date free cash flow to about $800 million. Our working capital initiatives, including inventory reduction, continue to pay off, as we reduce days on hand by 10 days compared to the third quarter of 2024, despite higher inventory levels associated with Paragon 28. We ended the quarter with approximately $1.3 billion in cash and cash equivalents. Now regarding our outlook for 2025. We are maintaining our 2025 reported revenue growth guidance of 6.7% to 7.7%, adjusted EPS guidance of $8.10 to $8.30, and free cash flow guidance of $1 billion to $1.2 billion. We are updating our 2025 organic constant currency revenue growth guidance of 3.5% to 4% from our prior range of 3.5% to 4.5%. Inside of this, we continue to expect consolidated pricing to be roughly flat for the full year and selling day differences to be a modest headwind to full year growth. Importantly, as Yvonne mentioned, this updated guidance range contemplates continued weakness in restorative therapies, a more measured outlook for certain international markets, and the slowdown in the U.S. revision market for both hip and knee persisting throughout the remainder of the year. Now let's walk through the moving parts that impact our reported revenue guidance. At recent rates, FX is now expected to be more favorable to our full year outlook than previously anticipated. At current rates, we now anticipate FX to contribute 50 to 100 basis points of growth in 2025. We continue to expect Paragon 28 to contribute around 270 basis points to reported sales growth in 2025. As previously communicated, we expect our operating margins to be down about 100 basis points versus 2024, which factors in our previously communicated tariff headwind of about $40 million. Adjusted net interest and other non-operating expenses are now expected to be approximately $280 million, down from $290 million in part due to lower borrowings on better cash flow. And we continue to expect our adjusted tax rate to be approximately 18% for the full year and fully diluted shares outstanding to be approximately 200 million shares. I'd like to close by thanking the entire ZB team for their hard work and dedication. We continue to make meaningful positive change across the business while investing to accelerate long-term growth. And with that, I'll turn the call back over to David.

Thank you, Sookie. Operator, let's open up for questions. In order for us to take as many questions as possible, please limit yourself to one question.

Operator, please go ahead.

Thank you. If you would like to ask a question, please signal by pressing star 1 on your telephone keypad. If you're using a speakerphone, please make sure your mute function is turned off to allow your signal to reach our equipment. Again, please press star 1 to ask a question.

We will take our first question from Robbie Marcus from JP Morgan.

Good morning, and thanks for taking the questions. Yvonne, I wanted to ask on, I would say, guidance in general. On the last quarter call, you talked about scratching 6% in third quarter, which was above consensus at the time, and you ended up at 5.0 for organic growth. And fourth quarter, or the full year guide is ticking down. So really the question is, you know, how are you thinking about guidance philosophy? What happened exactly in the quarter? And any preliminary thoughts on how we should be thinking about 2026, recognizing that excluding the easy comp from last year, we're sort of in a three plus percent growth range. Thanks.

Hey, good morning, Robbie and everybody. And thank you for asking that question. It's an extremely fair question. So let me unpack a few things here. So I said back in August that I would be very surprised if we didn't scratch 6%. And I'll tell you what, I'm indeed very surprised that we didn't over-deliver on such number. Not that we didn't scratch it, but rather that we didn't over-deliver on that 6%. For what is worth, it was actually an under-committed and over-delivered comment based on what we believe to be very strong data at hand at the time, with the U.S. in July growing around 7%, robust growth across the board, not just in one region, and in possession of a very solid pipeline of positive things happening across Zimmerbaum at that time, almost midpoint into the quarter. So, yes, I am very, very surprised. But Speaking of surprises, three things happened really late in the quarter with less than a week to go, which caused Zimmerbaum at around 120 basis points. And give me just a minute or two to go through some of these, and then we'll talk about guidance and philosophy and whatnot. But with a week to go in the quarter, three things happened. We saw a last-minute cancellation of distributed orders in emerging markets of Europe, mostly from the Middle East and Eastern Europe. Number two, our restorative therapies business, rarely talk about this business, is around $110 million annually, HA, hyaluronic acid injections. Here in the U.S., we made some pretty basic commitments by a fairly large amount, especially for the size of that business. And then thirdly, in Latin America, we missed our forecast by north of 15%, given some distributor challenges in the region. That's 15% of 1.5%. Again, that happened really, really late in the quarter. So non-core areas, non-core business, but painful, Robbie, by the time that you put all of them together, they tune up around $24 to $25 million. So again, just on those three things alone, you got another 120 basis points to the 5% that we're reporting today. In any given quarter, as you can imagine, when you run a complex company like Zimmer Biomed, in any given quarter, you're going to have a variety of these things happening. But to see all of these events happen at the same time, is unique to say the least, especially when you got, you know, just a few days to go to finish the quarter. I'm having budgeted somewhat conservatively for all of these three items that I'm talking about here today. Clearly, this has told me that we, or rather I, need to be far more measured in our external commentary. And you better believe, Robbie, that such change has started effective today. I own it. I say what I said. I had the data that we had And I don't anticipate that I'll be repeating this type of comments moving forward, even when the data starts to be as compelling as it was back in early August. So measured is the word when it comes to commentary and philosophy and guidance, or more measured is the word when, you know, talking about commentary and guidance moving forward. That said, Robbie, I will hope that the comments that we made or I made, non-prudent perhaps in hindsight, don't end up tarnishing what was otherwise a very solid quarter across a variety of key areas. So as you heard in the prepared remarks, we grew our U.S. business by 5.6%, delivering the best quarter in the U.S. in over two years. Our largest product franchise needs actually grew 5.3 globally on an organic constant currency basis, with hips delivering mid-single-digit growth. We had the best quarter in robots in quite some time. SET, another consistent quarter with the U.S. delivering close to upper single digit. EPS, as you heard from Suki, was another solid story. Even with softer revenue coming from these three key areas, we ended up delivering above expectation EPS. And guidance on EPS for the year remains untouched. You know, we've gone back to the original $8.10 to $8.30, even after dealing with tariffs, integrating two companies, and absorbing very meaningful commercial investments. So I can go on and on, but again, the comments, perhaps non-prudent, but the performance was there. I say what I said on it, and I'll make sure to be far more than a measure moving forward. Relative to the guidance for the rest of the year, to your question, it is very measured. We're very comfortable that we're going to deliver on that guidance. And once we get into 2026, we'll have a conversation around philosophy and what the guidance looks like for 2026. Thanks for the question. Again, it was very fair.

We'll go next to Travis Steed with Bank of America.

Hey, everybody. One follow-up to that question. I guess the 120 basis points this quarter, does that come back at some point? Is it a continued headwind in 26? Is it a positive or negative in 26? And I don't know if you can quantify that. And there were some comments on kind of a slowdown in the U.S. revision market. Does that continue as a headwind into next year as well? And But there was also some comments I noticed in the script where you remain highly disciplined on capital allocation. So just wanted to see what that means as you look into the next year as well.

Thank you, Travis. I'll let Suki talk about capital allocation here in a second. So this international noise, is it coming back in 2025 in the fourth quarter? Look, as I said, we're going to be measured. So we took that out of the guidance. So we're not counting on that revenue. from those three key areas to be back in 2025. If it does, that's great. Do we think that's going to continue in 2026? Again, too early to talk about that. But what I will tell you is that as we think about external commitments made for 2026, we're going to stay away from putting some of these revenue from non-core areas in our external commentary and the external guidance that we're going to be providing. So do you want to talk about capital allocation?

Yeah, sure. Let's start with a few data points. So, you know, this year we're going to be generating over a billion dollars of free cash flow, quite attractive. We're in excess of $1.6 billion, almost $1.7 billion of adjusted EBITDA. And we have a net debt leverage ratio in the very low three. So you can see there are some really strong fundamentals there, a very strong balance sheet with a significant amount of firepower. The way we think about that capital allocation then is we're going to prioritize businesses and acquisitions, assets that continue to move us into faster growth markets. that continue to accelerate in your term as well as long-term revenue. But we're going to do it in a prudent way. And I think you've seen that with the Paragon 28 acquisition, very exciting on a gram transaction that we've done quite recently, OrthoGrid, which has been a differentiator for us. So we're going to continue that path, but in a disciplined fashion as we always have. But that also, that very attractive balance sheet always gives us also strategic optionality to do share buybacks. opportunistically as we see fit based on market conditions. So the net takeaway is that nothing's really changed fundamentally on our capital allocation strategy. If anything, it continues to get stronger.

And Travis, you had a question there around the revision market that I failed to answer. So look, it's too early to tell. It's fairly choppy. One quarter we see more revisions than the next. So it's a bit hard to predict. It's too early to tell whether we're going to see softness in 2026 when it comes to revisions. But again, going back to guidance philosophy, we'll account for that at the time we provide guidance for 2026.

Thank you. Thank you.

We'll go next to David Roman with Goldman Sachs.

Thank you. Good morning, everybody. I was hoping maybe you could contextualize the performance in 2025 against the LRP targets that you laid out, I guess, about a year and a half ago now. As I think about the guidance here, the midpoint of the range being in the 3.5% to 4% range and the 4% to 6% that you had provided, you would need each of the next two years to be in the 5% to 6% range to end up at the midpoint of your LRP. And I think, Yvonne, when you talk through some of the dynamics that came up late in the quarter, those things like that kind of just happen. So does a material acceleration of growth require an everything-goes-right approach? set of circumstances to get into the LRP range, and is it feasible to see growth in the 5 to 6 percent range going forward to get back on track with the LRP?

Thanks, David. So, present and future kind of question here. So, in the present, second half of 2025, we are growing mid-single-digit or above. So, actually, mid-single-digit or above. So, we are there. As we think about 26 and 27, give us a chance to get into February. We'll discuss what 26 and 27 looks like. I'll tell you, we think of the three-year plan across three components. You've got market dynamics, innovation dynamics, and commercial execution dynamics. We know that from a market standpoint, the market supports companies delivering mid-single-digit growth. Four-four-and-a-quarter market dynamics, so the basin is there for companies to deliver mid-single-digit or above. As you move to innovation, the innovation cycle is working out. That is, again, why in the second half of 2025, we are delivering that mid-single-digit growth rate. And let's evaluate the sustainability or acceleration of that innovation cycle as we get into 26 and 27. But we're very confident that the innovation cycle is real and more things to come. And then you got the lingering question on commercial execution. Do we feel like today, with the fragility we got in some non-core areas, with the changes we're making in the U.S., that can be an accelerator, that can be something that is going to drive sustainable mid-single-digit revenue growth? That's something we're evaluating, and that's something that we're going to discuss coming early 2026. But market is what it needs to be. Innovation is what it needs to be. We've got to address some execution issues here.

Thanks for the question.

We'll go next to Caitlin Roberts with Canaccord Genuity.

Hi, great. Thanks for taking my question. I guess just turning to your product pipeline, you've received clearance for your iodine technology in HIPS recently in Japan and then also announced the FDA granted the technology breakthrough device designation in the U.S. If you could talk through these developments and just the timeline for the launch in the U.S. and or further indications beyond HIPS, that would be great.

Hey, thanks for the question, Caitlin. So, exciting product launch. We've been working on this technology in Japan for over a decade. It's one of the most complex clinical trials that I've seen in my 31 years in MedTech, and it's great news that we got approval in Japan. This is a $1.3 billion market, the second largest market after the U.S. We're going to be launching at the end of 2025. And yes, this is going to be a meaningful revenue contributor for 2026. And again, we'll talk about it once it's time to talk about it with really good pricing. It is differentiated technology. There's nothing like that. It does suppress or prevent biofilm formation on the implant with, again, robust clinical data over 10 years. It is technology that eludes over a prolonged period of time. So, again, unique and something that we think is very compelling. Most importantly, the FDA thinks it's also very compelling. This happens to be one product from Zimmer Biomed that is getting the breakthrough designation here in the U.S. That doesn't mean that we're going to be launching immediately. That doesn't mean that the approval cycle is going to be shorter. But it does mean that we get to work with the FDA immediately. you know, elbow to elbow in launching this technology at the right price in the U.S. I'm not going to commit to a date in that we're launching iodine-treated devices in the U.S., but it is breakthrough, so we like what we see. We're going to start with hips, and then we're going to move into knees, shoulders, and other categories in due time. But again, breakthrough technology, and thanks for the question.

Thanks. We'll go next to Patrick Wood with Morgan Stanley.

Beautiful. Thank you so much. You know, you guys mentioned, obviously, some of the refocusing on growth when it came to the incentive structure. Was that at, like, the rep level? Was that the divisional head level? Just any more details on how you're structuring the incentive plan to kind of push people towards growth?

Thanks.

Patrick, good morning. It's at all levels. So this is a company that has gone through a lot over the last decade. You know that. And we failed to put the right incentive plan across the board. And today we make external commitments around revenue, earnings per share, and free cash flow. Yesterday, folks at different levels were not getting paid on those three levels of commitment. Today, I can tell you that every senior manager that owns a P&L here at Zimmer Baume gets paid on revenue growth, earnings per share, performance, and free cash flow generation. As you click down to the commercial structures, we are paying people on growth. We are paying people on margin. And that goes all the way to the sales rep level. We hold sales reps across Zimmer Biomed accountable for pricing dynamics. And if you're not growing on revenue, if you're not growing on margin, the things that you can control within margin, you're not going to get paid your full compensation. So this is something that has been choppy over the last, you know, call it three or five years. But I can tell you that the discipline is there today. Thanks, Bajie.

We'll go next to Larry Beagleson with Wells Fargo.

Good morning. Thanks for taking the question. Yvonne, it looks like the recon market improved in the third quarter versus second quarter. What are you seeing into Q4? And Suki, you have this goal of EPS of 1.5 times sales. Is there anything you would highlight for next year, like the tariffs? that would make it difficult to achieve in 2026. Thanks.

Hey, Larry, good morning. Yes, we did see an acceleration at Q3 over Q2. Overall, we look at trends, and if you look at post-COVID dynamics and you take out the backlog, we see the market as being healthy. And I think my peers that have reported already have said the same thing, that the markets are stable, a combination of volume and price. In terms of Q4, look, I'm going to learn my lesson, so I'm going to tell you anything about market dynamics in Q4. I'm just going to tell you that the market overall is pegged to be around 4%. Suki?

Yeah, thanks for the question, Larry. I think you'll see this year, and if you look back even over the last several years, we've been incredibly disciplined in growing margins and growing our bottom line in concert or better than our top line. As Yvonne noted in his prepared remarks earlier, if you look at our earnings per share guidance for this year. We're basically right where we started the beginning of the year, and that's even after stepping over the tariff burden as well as integrating Paragon 28 as well as Monogram. So as you can see, we've been quite disciplined throughout the P&L and all the way down to cash flow. It's too early to talk about 2026 at this time. As Yvonne said, we'll come out in February and give a lot more color on that. What I will point to, though, is, again, the strong performance this year. which marks a number of consecutive years of very strong performance on margin and earnings.

All right. Thank you.

We'll go next to Rick Wise with Stiefel.

Good morning. Sorry. Good morning, Yvonne Hisuki. I'm hoping, Yvonne, I can ask you to talk a little bit more about innovation, the very visible innovation that's the innovation pipeline at Samurai at Biomet. I hope you would agree that innovation done well should drive, again, done well, should drive steadily improving pricing, share gain, new accounts, better margins, among many other factors. And I feel like you're well underway with your wave one, the mag seven, and There are others. These are largely launched, still rolling out, and much more to go. Wave two, you're highlighting it today, Monogram, the Iodine HIP, et cetera, and others. So my question, sorry for the long windup, is where are we in that wave one rollout process and impact? I feel like third quarter in the United States is showing I mean, please correct me if you think I'm wrong, is showing clear, positive, concrete signs of that early wave one rollout with, again, more to come. So the bottom line is, when can we expect a more significant, meaningful impact from your actually impressive pipeline?

I love the question, Rick, and good morning. So you spoke about waves. So maybe let's segment innovation of three waves. So wave number one was catching up on certain categories where we're absent. And that's the lion's share of what we're doing, what we call the Magnificent Seven. And as you saw in the U.S., we delivered 5.6% growth. And this is largely induced by this Magnificent Seven. And in my prepared remarks, I offered all kinds of commentary around adoption rates for Oxford parcels are endless, above expectations. Z1 triple tapers, we're regaining market share. I love where we are with ortho grid and navigation. Lots of accounts that we have lost to competitors that we are regaining. I like where we are with the NE franchise. So wave one, catching up, Magnificent Seven is working. And it should accelerate as we get into 2026. So that's wave one. Wave two is moving from catching up what I call competitive-centric innovation, things that others were doing that we failed to do. With that behind, we have moved already into wave two, customer-centric innovation. How do we change the standard of care by being first to market in new technologies? That's fully autonomous and semi-autonomous robotics. That's next-generation digital ecosystem, which we are doing. That's the example that I provided to Caitlin around IOTA encoded devices, first to market with IOTA. breakthrough technologies. So we are deep already into that second innovation cycle. So call that wave two. And then it's wave three. How do we apply these innovation capabilities into spaces outside of core orthopedics? And that's going to come largely or mostly from inorganic means. And I love the fact that we got the balance that we have to get into that space. So again, three different waves of innovation catching up, don't working. Now we need to accelerate it. uh customer-centric innovation and i provided two or three examples and yes uh we look forward to bringing innovation capabilities outside of court also i love the question rick thank you we'll go next to matt taylor with jeffries hi guys thanks for taking the question um you know i i know that the the uh guidance update here includes a more measured outlook for these international markets in the near term i guess would you expect some pickup in those areas that you saw softness in in q3 in in 2026 just at a high level thanks for the question matt and i think travis does something similar and i failed to answer no we're taking those hiccups uh outside of uh any consideration for 2026. and again i'm not going to talk on whether they're going to stick around or not um we're going to take them out. That's not in the guidance for 2026, the way we think about guidance today, again, too early. And they're not in the guidance for the rest of 2025. So as you think about narrowing the guidance from 3.5 to 4.5 to now 3.5 to 4, So thinking of midpoint in around 3.75, not thinking that's where we're going to land, that's a 25 basis point reduction or roughly $20 million. And that's largely induced by some of this volatility that we have seen in some of these non-core areas.

Thanks.

Thank you.

We'll go next to Joanne Wench with Citi.

Good morning, and thank you for taking the question, and I'm going to apologize for it in advance. I think what many of us are asking today is, given the miss on the third quarter and the updated guidance for 25, how should we think about 26? And I'm respectful. It's too early to give that guidance. But is there a way to give us some maybe headwinds and tailwinds? anything that you can help to sort of set our models correctly so that when we do get to guidance, we're not surprised. Thank you.

Thank you, Joanna. No, you don't need to apologize. You're doing your job. So, again, early to talk about 2026, but I'll go back to the three key components of guidance. Markets, commercial execution, and innovation. Markets is definitely something that we have a lot of data on, and we like where these markets are at. On innovation, as Prem answered to Rick earlier, love where we are with Magnificent 7. Love the opportunities with things like IOTA and core devices in Japan and other markets. I love the fact that we're moving some of this innovation from the U.S. now into other geographies. So that's definitely something that gives us a lot of confidence. We just need to evaluate some of this fragility around commercial execution. So again, the sum of all parts will inform the guidance in terms of what is the right guidance. will be measured. We'll make sure that whatever we say externally has a very high probability of being overachieved.

Thanks for the question.

We'll go next to Matthew O'Brien with Piper Sandler.

Morning. Thanks for taking the question. Can we just talk about the U.S. knee market specifically? And I know you've got all these new products coming out. Can you talk about some of the mixed benefit that you're getting already from these new products? And then I don't have perfect information, and one of your bigger competitors hasn't reported, I get that. But I'm still showing you're losing market share here in Q3 in the U.S., and it's a trend that's been going on for several years. So what I'm wondering is with some of these mixed benefits you might be getting, and maybe volume benefits that you could be starting to realize as you get back into some of these accounts. Is that something where there's kind of a lag effect where it could really rebound in 26 from a share perspective? Or do you need something else? I don't know if it's Monogram, et cetera, or some of these new ROSA placements to really help you stem some of the U.S. knee share loss. Thank you.

Another very fair question. So are we losing markets in the U.S.? Let's see what the quarter looks like once everybody reports and we're able to analyze all the different dynamics. We are losing markets here. I'll tell you, Matt, we're doing so at a much slower rate than we did before, which again validates that the innovation cycle is working out. And as we get into 2026, we're going to be in a much deeper stage of this innovation cycle with more stuff to come. So again, hard to tell what's going to happen in 26. But I like the momentum. I like the sequential growth we've seen in the U.S. I like the 5.6% growth in the U.S. I like where we are with needs in the U.S. Increased quarter over quarter, now 3.5. And HIPs, look, it was not too long ago, Matt, that we're losing market share at the tune of 500 to 600 basis points. And now we're growing mid-single digit in the U.S. So if we are losing market share in the U.S., it's not at the same pace as before. And this is still early in this innovation cycle. In terms of margin, yes, every single one, if not most of these new products that we're launching have a better margin profile. Whether it's Oxford Parcel Cementless, whether it's Persona Revision in Europe, whether it's Persona Oceotide, where we get better margin and definitely get a sort of wallet opportunity, it's not just launch innovation, it's getting a better margin profile with this innovation. And relative to 2026, again, I look forward to the conversation in early 2026. Thanks for the question.

We'll go next to Ed Ridley with Rothschild and Company Redburn.

Hi, thank you very much. First of all, just a quick one on Paragon. Can you speak to the organic growth there that you're seeing behind the acquisition benefit and the momentum? And given Johnson & Johnson's announcement, a long-duration exit tends to throw up opportunities for others. Can you speak a little to that and how you think that might be some opportunity there, both in terms of personnel or potentially geography?

Hey, thanks for the question, Ed. So, Paragon 28, maybe let's take a step back and recall what the thesis behind acquiring this asset was. We wanted to acquire something that was growing higher. We've gotten a higher market or a higher market growth rate. That's Paragon 28. This market is growing solidly in the, call it, 6% to 8% range. We wanted to build a platform, not just buying one company. We wanted to build a platform around lower extremities. We've done that, whether it's lower trauma, whether it's foot and ankle and other components, biologics, we've got that going on. We wanted to have a more meaningful presence in the ASD space. That's enabling that. I wanted to buy a company that had innovation today, but a pipeline for tomorrow. And all of that remains true with Paragon 28. The organic performance for the quarter was in the upper single digit range. We are stabilizing some of the early, I guess, contract friction that you can see in this category. But everything is looking solid. We're not touching the guidance for the year 2025. we continue to see great momentum with commercial execution and again launching new products. And we think of this asset as something that needs to be growing double digit for a period of time. You know, there may be some hiccups, you know, every once in a while. But overall, the organic growth of Paragon 28 should remain in the teens. Thanks. And sorry, relative to J&J, look, I'm not going to comment on the disruption there. I'm going to be respectful to my peers out there. But there is disruption. Every time you go through a spin-off, diversity tour, we're seeing it here at Zimmer Biomed. There is going to be some level of disruption, and there are customers that are going to be asking whether Zimmer Biomed offers a better solution, and there may be some short-term opportunities. But again, I'm going to be respectful to my peers and don't comment too much on this. Thank you.

We'll go next to Matt Mixick with Barclays.

Hey, thanks so much for taking the question. One follow-up on the iodine HIP. I encoded the implants and then just a clarification on some of the issues that impacted Q3. So on the sort of new implant line, you mentioned FDA breakthrough designation. I'm wondering if that's a, if that turns into a premium product, understanding that, you know, premium and negotiations for implant prices engages hospitals and requires, you know, value assessment committees and sort of that pathway? Does this effectively kind of drive mix in a significant way? Or, Yvonne, are you thinking about this more as a way of catching more volumes here just because of the clinical benefits, the product you're going to bring. And I guess with FDA designation or breakthrough designation, is there a possibility for CMS to pass through there to support a price lift? And I have one quick clarification if I could, but thanks.

Yeah, so on iodine, yes to all of the above, Matt. So again, a breakthrough designation in the U.S. does enable premium pricing, better reimbursement dynamics. You go through value committees at a faster pace. And the assumption is that once we have this product in the U.S., it's going to command higher pricing. But let's not talk about the future and focus on the present. This has already happened in Japan. So with this approval in Japan, it's a similar dynamic. We are going to get a pretty significant price uplift in the country. And again, it's the second largest market for similar biomed. We're going to get a level of reimbursement that is far better than other devices in the market. So the answer to either than is yes to all of the above. Breakthrough does deliver better pricing dynamics, faster adoption opportunities through committees and whatnot. What was your second question, Matt? Apologize.

Yeah, sure. So second, just to follow up on the restorative therapies, you know, shortness or softness or, you know, whatever you would describe it as, lower inspected orders. That's just to be crystal clear. I apologize. I should know this probably. But is this bone growth stimulators? Is this, you know, glue? And also, I understand there's some additional competition in bone growth, not that it's a business we... spent a lot of time thinking about these days, but was that a factor, any color on the product lines, and what the dynamics were around that would be helpful?

Yeah, absolutely. So first things first, let me simplify. When we talk about restorative therapies, basically talking $110, $120 million of revenue annual on one product. That's HA injections, so that's hyaluronic acid injections. And what happened is quite simple. I will say three things. One, we didn't budget adequately. So that's a mistake we're not going to repeat. We had some challenges on commercial execution because the focus has been elsewhere. And then thirdly, as you probably recall, there were some reimbursement changes in the U.S. through CMS that we thought that were behind, and they're not behind. So it's a really acute element of pricing that impacts this business. But I will say the sum of all parts is mostly commercial execution. And again, as we think about 2026, I keep repeating myself, we're not going to offer commentary. But when it comes to this non-core business, we're going to be far more measured in the expectations that we have from restorative therapies going into the year.

Thank you. Very helpful. Thanks.

We'll go next to Daniel Antofi with UBS. Hi. Good morning.

So sorry about that. Thanks for taking the question, guys. Just a follow-up question, Yvonne. You mentioned some high-level personnel changes and things like that. I'm just curious about how far into that you are and sort of how we should think about that potentially impacting the next few quarters as far as any potential disruption or Or do you feel like those are pretty easily transitional? It's not much of a transition, so we shouldn't expect any issues there. Thank you so much.

Hey, Daniel, good morning. Thanks for the question. So first things first, the organization is always evolving. Going back to strategic pillar number one, we're going to have the right people in the right jobs. People, folks that know how to make commitments and deliver on commitments. And once those things don't happen, you know, we'll have to make changes at the right pace. Those changes are embedded in the guidance we're providing. So as we think about these guidance on both revenue and EPS, the assumption of these changes is already in there. On the commercial changes in the U.S., look, we're going a bit faster than before, but we were working on the commercial channel for quite some time, and that's also embedded in 2025, and it will be part of 2026. So long-winded answer to say is reflect on the guidance, and we look forward to making these changes.

Okay. Thank you.

Thank you, Daniel.

This concludes the question and answer portion of today's call. I would like to turn the call back over to Ivan for any closing comments.

Thank you very much. So my closing comments is that we continue to be proud of the evolution of this business, the improvements that we make in this business. We're going to stick to the three key priorities of organization. And again, as we think about the rest of the year, we're very confident we're going to achieve the guidance. And as we think about 2026, we continue to see health when it comes to market dynamics. We are highly encouraged about our innovation cycle. And we will address the fragility that we get in some pockets when it comes to commercial execution. Thank you for your time this morning.

This concludes today's call. Thank you for your participation. You may now disconnect.